KORU Medical Systems, Inc. reported a significant increase in financial performance for the fiscal year ending December 31, 2025, with net revenues reaching $41.1 million, a 22.2% rise from $33.6 million in the previous year. This growth was primarily driven by an 11.0% increase in domestic core revenues, totaling approximately $28 million, and an impressive 80.0% surge in international core revenues, which amounted to nearly $10.9 million. However, the company experienced a 5.6% decline in revenues from its pharma services and clinical trials segment, which contributed $2.3 million.
The company's gross profit also saw a notable increase, rising to $25.6 million, up 20.0% from $21.3 million in 2024. Despite this growth, the gross margin slightly decreased to 62.3% from 63.4% the previous year, attributed to higher material costs and tariff-related charges. Operating expenses increased to $28.6 million, up from $27.8 million, primarily due to higher selling, general, and administrative costs, which rose by 8.1% to $23.4 million. Research and development expenses decreased by 16.6% to $4.4 million, reflecting a strategic shift in resource allocation.
KORU Medical's operational developments included a focus on expanding its market presence, particularly in the subcutaneous immunoglobulin (SCIg) market, which is expected to grow due to increasing diagnoses of Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company also aims to enhance its product offerings and market penetration through ongoing clinical and product innovation. As of December 31, 2025, KORU employed 73 full-time staff, with a diverse workforce comprising approximately 48% female and 38% minority employees.
Looking ahead, KORU Medical anticipates continued growth driven by its strategic initiatives and market trends. The company plans to invest in research and development to support new product launches and expand its share in the SCIg market. However, it acknowledges potential risks, including reliance on a limited number of distributors for sales, regulatory compliance challenges, and the need for additional capital to fund future growth. The company ended the year with $8.9 million in cash and cash equivalents, indicating a solid liquidity position to support its operations in the near term.
About KORU Medical Systems, Inc.
KORU Medical designs, manufactures, and markets patient-centric infusion systems, primarily for subcutaneous drug delivery in home and clinical settings. Its flagship FREEDOM System supports immunoglobulin therapies and collaborates with biopharmaceutical companies on novel treatments. The company emphasizes innovation, regulatory compliance, and global market expansion to provide safe, effective, and easy-to-use infusion solutions for chronic illness management.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.